Because the overwhelming majority of medical and pharmaceutical research is directed toward products that affect people in affluent countries, it targets only part of the global burden of disease. Some government- and foundation-funded research addresses diseases that primarily affect poor people, but these efforts are not systematic and do not use the incentives that work well to drive pharmaceutical innovation elsewhere.